XML 94 R76.htm IDEA: XBRL DOCUMENT v3.3.1.900
Segment Information Segment Information (Details) - USD ($)
$ in Millions
1 Months Ended 3 Months Ended 12 Months Ended
Dec. 31, 2013
Dec. 31, 2015
Sep. 30, 2015
Jun. 30, 2015
Mar. 31, 2015
Dec. 31, 2014
Sep. 30, 2014
Jun. 30, 2014
Mar. 31, 2014
Dec. 31, 2015
Dec. 31, 2014
Dec. 31, 2013
Segment Reporting Information [Line Items]                        
Depreciation and amortization                   $ 1,427.7 $ 1,379.0 $ 1,445.6
Revenue   $ 5,375.6 $ 4,959.7 $ 4,978.7 $ 4,644.7 $ 5,121.3 $ 4,875.6 $ 4,935.6 $ 4,683.1 19,958.7 19,615.6 23,113.1
Other Revenue, Net                   808.1 788.4 707.5
Long-Lived Assets [1] $ 8,741.3 8,696.6       8,547.2       8,696.6 8,547.2 8,741.3
Asset impairment, restructuring, and other special charges   (144.9) (42.4) (72.4) (108.0) (401.0) (36.3) 0.0 (31.4) (367.7) (468.7) (120.6)
Selling, General and Administrative Expense                   (6,533.0) (6,620.8) (7,125.6)
Income before income taxes                   2,790.0 3,000.3 5,889.3
Cost of sales   1,389.2 1,236.9 1,218.4 1,192.7 1,253.1 1,267.0 1,189.7 1,222.7 5,037.2 4,932.5 4,908.1
Acquired in-process research and development (57.1) (199.0) 0.0 (80.0) (256.0) (105.2) (95.0) 0.0 0.0 (535.0) (200.2) (57.1)
Gain (Loss) on Contract Termination                   0.0 0.0 495.4
Other-net, (income) expense   44.7 $ 86.5 $ (123.3) $ 92.7 137.2 $ 93.5 $ 53.8 $ 56.0 100.6 340.5 518.9
Amortization of Intangible Assets                   631.8 535.9 555.0
Gains (Losses) on Extinguishment of Debt                   166.7 0.0 0.0
United States [Member]                        
Segment Reporting Information [Line Items]                        
Revenue [2]                   10,097.4 9,134.1 12,889.7
Long-Lived Assets [1] 4,649.6 4,576.8       4,566.2       4,576.8 4,566.2 4,649.6
Europe [Member]                        
Segment Reporting Information [Line Items]                        
Revenue [2]                   3,943.6 4,506.7 4,338.4
Long-Lived Assets [1] 2,469.7 2,306.4       2,401.5       2,306.4 2,401.5 2,469.7
JAPAN                        
Segment Reporting Information [Line Items]                        
Revenue [2]                   2,033.1 2,027.1 2,063.8
Long-Lived Assets [1] 81.1 89.2       80.4       89.2 80.4 81.1
Other Foreign Countries [Member]                        
Segment Reporting Information [Line Items]                        
Revenue [2]                   3,884.6 3,947.7 3,821.2
Long-Lived Assets [1] $ 1,540.9 1,724.2       $ 1,499.1       1,724.2 1,499.1 1,540.9
Human Pharmaceutical Products [Member]                        
Segment Reporting Information [Line Items]                        
Other Depreciation and Amortization                   720.7 790.0 838.8
Total segment [Member]                        
Segment Reporting Information [Line Items]                        
Other Depreciation and Amortization                   801.5 848.8 890.6
Income before income taxes                   4,624.6 4,226.4 6,126.6
Endocrinology [Member]                        
Segment Reporting Information [Line Items]                        
Revenue                   7,036.8 6,939.0 7,304.4
Neuroscience [Member]                        
Segment Reporting Information [Line Items]                        
Revenue                   2,935.4 3,596.5 7,216.2
Oncology [Member]                        
Segment Reporting Information [Line Items]                        
Revenue                   3,509.8 3,393.0 3,268.5
Cardiovascular [Member]                        
Segment Reporting Information [Line Items]                        
Revenue                   3,068.0 3,053.5 2,923.2
Other Pharmaceuticals [Member]                        
Segment Reporting Information [Line Items]                        
Revenue                   227.7 287.0 249.3
Human Pharmaceutical Products Total [Member]                        
Segment Reporting Information [Line Items]                        
Revenue                   16,777.7 17,269.0 20,961.6
Income before income taxes                   4,026.7 3,604.6 5,521.0
Animal Health Products [Member]                        
Segment Reporting Information [Line Items]                        
Other Depreciation and Amortization                   80.8 58.8 51.8
Revenue                   3,181.0 2,346.6 2,151.5
Income before income taxes                   597.9 621.8 605.6
Corporate, Non-Segment [Member]                        
Segment Reporting Information [Line Items]                        
Asset impairment, restructuring, and other special charges                   (367.7) (468.7) (120.6)
Selling, General and Administrative Expense                   0.0 (119.0) 0.0
Acquired in-process research and development                   (535.0) (200.2) (57.1)
Amortization of Intangible Assets [3]                   (626.2) (530.2) (555.0)
Amylin [Member] | Corporate, Non-Segment [Member]                        
Segment Reporting Information [Line Items]                        
Gain (Loss) on Contract Termination                   0.0 0.0 495.4
Cymbalta [Member] | Neuroscience [Member]                        
Segment Reporting Information [Line Items]                        
Revenue                   1,027.6 1,614.7 5,084.4
Humalog [Member] | Endocrinology [Member]                        
Segment Reporting Information [Line Items]                        
Revenue                   2,841.9 2,785.2 2,611.2
Humulin [Member] | Endocrinology [Member]                        
Segment Reporting Information [Line Items]                        
Revenue                   1,307.4 1,400.1 1,315.8
Forteo [Member] | Endocrinology [Member]                        
Segment Reporting Information [Line Items]                        
Revenue                   1,348.3 1,322.0 1,244.9
Evista [Member] | Endocrinology [Member]                        
Segment Reporting Information [Line Items]                        
Revenue                   237.3 419.8 1,050.4
Trajenta (BI) [Member] | Endocrinology [Member]                        
Segment Reporting Information [Line Items]                        
Revenue                   356.8 328.8 249.2
Trulicity [Member] [Member] | Endocrinology [Member]                        
Segment Reporting Information [Line Items]                        
Revenue                   248.7 10.2 0.0
Other Endocrinology [Member] | Endocrinology [Member]                        
Segment Reporting Information [Line Items]                        
Revenue                   696.4 672.9 832.9
Zyprexa [Member] | Neuroscience [Member]                        
Segment Reporting Information [Line Items]                        
Revenue                   940.3 1,037.3 1,194.8
Strattera [Member] | Neuroscience [Member]                        
Segment Reporting Information [Line Items]                        
Revenue                   784.0 738.5 709.2
Other Neuroscience [Member] | Neuroscience [Member]                        
Segment Reporting Information [Line Items]                        
Revenue                   183.5 206.0 227.8
Alimta [Member] | Oncology [Member]                        
Segment Reporting Information [Line Items]                        
Revenue                   2,493.1 2,792.0 2,703.0
Erbitux [Member]                        
Segment Reporting Information [Line Items]                        
Revenue                   485.0 373.3 373.7
Other Revenue, Net                   309.4 327.2 315.2
Erbitux [Member] | Oncology [Member]                        
Segment Reporting Information [Line Items]                        
Revenue                     373.3 373.7
Other Revenue, Net                   485.0    
Cyramza [Member] | Oncology [Member]                        
Segment Reporting Information [Line Items]                        
Revenue                   383.8 75.6 0.0
Other Oncology [Member] | Oncology [Member]                        
Segment Reporting Information [Line Items]                        
Revenue                   147.9 152.1 191.8
Cialis [Member] | Cardiovascular [Member]                        
Segment Reporting Information [Line Items]                        
Revenue                   2,310.7 2,291.0 2,159.4
Effient [Member] | Cardiovascular [Member]                        
Segment Reporting Information [Line Items]                        
Revenue                   523.0 522.2 508.7
Other Cardiovascular [Member] | Cardiovascular [Member]                        
Segment Reporting Information [Line Items]                        
Revenue                   234.3 240.3 255.1
BI compounds [Member]                        
Segment Reporting Information [Line Items]                        
Other-net, (income) expense   $ 92.0                    
BI compounds [Member] | Corporate, Non-Segment [Member]                        
Segment Reporting Information [Line Items]                        
Other-net, (income) expense                   $ 0.0 $ 92.0 $ 0.0
Minimum [Member] | Sales Revenue, Goods, Net [Member]                        
Segment Reporting Information [Line Items]                        
Concentration Risk, Percentage                   9.00% 8.00% 13.00%
Minimum [Member] | Accounts Receivable [Member]                        
Segment Reporting Information [Line Items]                        
Concentration Risk, Percentage                   12.00% 9.00%  
Maximum [Member] | Sales Revenue, Goods, Net [Member]                        
Segment Reporting Information [Line Items]                        
Concentration Risk, Percentage                   15.00% 14.00% 19.00%
Maximum [Member] | Accounts Receivable [Member]                        
Segment Reporting Information [Line Items]                        
Concentration Risk, Percentage                   16.00% 15.00%  
Fair Value Adjustment to Inventory [Member] | Corporate, Non-Segment [Member]                        
Segment Reporting Information [Line Items]                        
Cost of sales                   $ (153.0) $ 0.0 $ 0.0
Long-term Debt [Member] | Corporate, Non-Segment [Member]                        
Segment Reporting Information [Line Items]                        
Other-net, (income) expense [4]                   $ (152.7) $ 0.0 $ 0.0
[1] (2) Long-lived assets consist of property and equipment, net, and certain sundry assets.
[2] (1) Revenue is attributed to the countries based on the location of the customer.
[3] (2) In 2015, the measurement of segment profitability was changed to exclude certain amortization of intangible assets. The prior periods have been adjusted to conform with the 2015 presentation.
[4] (1) We recognized pretax net charges of $152.7 million for the year ended December 31, 2015, attributable to the debt extinguishment loss of $166.7 million from the purchase and redemption of certain fixed-rate notes, partially offset by net gains from non-hedging interest rate swaps and foreign currency transactions associated with the related issuance of euro-denominated notes.